Investigational drug · Phase 2
GST-HG131
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "GST-HG131"
First trial start
2023
Dec 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GST-HG131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GST-HG131" as an intervention, largest first.
- Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 TabletsPivotal-lookingStatus unknown
Fujian Cosunter Pharmaceutical Co. LtdIndustry
NCT04499443 · 124 participants (planned) · Start Aug 18, 2020 · Primary completion Mar 31, 2021
Drug: GST-HG131 tablets; Placebo · For: Hepatitis B
Sites: Changchun, China
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07709520 · 80 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 1, 2026
Drug: GST-HG141; GST-HG131 and 1 more · For: Chronic Hepatitis B
Sites: Beijing, China
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT06263959 · 45 participants (planned) · Start Dec 26, 2023 · Primary completion Apr 1, 2025
Drug: GST-HG131; Placebo to match GST-HG131 · For: Chronic Hepatitis B
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.
Guo Y, Xu Z, Li Y, et al. · Liver Int 2026
- Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.
Hu Y, Sun F, Yuan Q, et al. · Bioorg Med Chem Lett 2022
- Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li X, Liu Y, Yao H, et al. · Antimicrob Agents Chemother 2022
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.